Biosynex SA (EPA:ALBIO)
France · Delayed Price · Currency is EUR 0.8300
+0.0120 (1.47%)
Nov 6, 2026, 5:35 PM CET
Biosynex Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 89.94 | 95.19 | 101.17 | 92.98 | 196.59 | 382.53 |
Other Revenue | -0.06 | - | - | - | - | - |
| 89.88 | 95.19 | 101.17 | 92.98 | 196.59 | 382.53 | |
Revenue Growth | -12.19% | -5.90% | 8.81% | -52.70% | -48.61% | 148.57% |
Cost of Revenue | 41.7 | 42.84 | 43.75 | 43.85 | 94.26 | 176.12 |
Gross Profit | 48.18 | 52.36 | 57.42 | 49.13 | 102.33 | 206.41 |
Selling, General & Admin | 30.4 | 32.93 | 41.38 | 36.06 | 21.44 | 17.25 |
Amortization of Goodwill & Intangibles | - | - | - | - | 5.72 | - |
Other Operating Expenses | 8.21 | 10.93 | 16.06 | 24.6 | 25.64 | 41.9 |
Operating Expenses | 35.74 | 78.4 | 84.95 | 85.28 | 63.44 | 65.76 |
Operating Income | 12.44 | -26.05 | -27.53 | -36.15 | 38.88 | 140.65 |
Interest Expense | -4.44 | -4.44 | -3.33 | -2.08 | -0.5 | -0.35 |
Earnings From Equity Investments | -0.14 | -0.17 | -0.1 | -1.51 | -5.57 | -2.68 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -0.02 | - | - | - |
Other Non Operating Income (Expenses) | 5.89 | 1.52 | 0.01 | 3 | 0.75 | 0.35 |
EBT Excluding Unusual Items | 13.65 | -29.23 | -30.98 | -36.74 | 33.56 | 137.98 |
Impairment of Goodwill | -21.28 | -21.28 | -8.8 | -1.26 | - | - |
Gain (Loss) on Sale of Investments | 5.73 | 5.73 | -2.88 | -3.98 | -3.45 | - |
Other Unusual Items | -11.26 | -14.46 | -2.09 | 2.3 | -5.93 | -1.04 |
Pretax Income | -13.15 | -59.24 | -44.75 | -39.68 | 24.18 | 136.94 |
Income Tax Expense | 0.64 | -1.1 | -1.36 | -2.56 | 8.57 | 32.94 |
Earnings From Continuing Operations | -13.79 | -58.14 | -43.4 | -37.12 | 15.61 | 104 |
Minority Interest in Earnings | - | -0.08 | 0.07 | 0.18 | 0.04 | - |
Net Income | -13.79 | -58.22 | -43.33 | -36.95 | 15.66 | 104 |
Net Income to Common | -13.79 | -58.22 | -43.33 | -36.95 | 15.66 | 104 |
Net Income Growth | - | - | - | - | -84.95% | 231.54% |
Shares Outstanding (Basic) | 19 | 18 | 11 | 11 | 10 | 10 |
Shares Outstanding (Diluted) | 19 | 18 | 11 | 11 | 10 | 10 |
Shares Change | 27.99% | 71.42% | 0.41% | 3.96% | -0.86% | 16.59% |
EPS (Basic) | -0.73 | -3.16 | -4.03 | -3.45 | 1.53 | 10.08 |
EPS (Diluted) | -0.73 | -3.16 | -4.03 | -3.45 | 1.52 | 10.01 |
EPS Growth | - | - | - | - | -84.81% | 184.38% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -8.57 | -14.96 | -49.2 | -32.83 | 90.82 |
Free Cash Flow Per Share | - | -0.47 | -1.39 | -4.59 | -3.19 | 8.74 |
Dividend Per Share | - | - | - | - | - | 2.000 |
Dividend Growth | - | - | - | - | - | 900.00% |
Gross Margin | 53.60% | 55.00% | 56.76% | 52.84% | 52.05% | 53.96% |
Operating Margin | 13.84% | -27.36% | -27.21% | -38.88% | 19.78% | 36.77% |
Profit Margin | -15.34% | -61.16% | -42.83% | -39.74% | 7.96% | 27.19% |
Free Cash Flow Margin | - | -9.01% | -14.79% | -52.91% | -16.70% | 23.74% |
EBITDA | 2.05 | -13.64 | -15.8 | -23.95 | 60.25 | 142.69 |
EBITDA Margin | 2.28% | -14.33% | -15.62% | -25.75% | 30.65% | 37.30% |
D&A For EBITDA | -10.38 | 12.41 | 11.73 | 12.2 | 21.36 | 2.04 |
EBIT | 12.44 | -26.05 | -27.53 | -36.15 | 38.88 | 140.65 |
EBIT Margin | 13.84% | -27.36% | -27.21% | -38.88% | 19.78% | 36.77% |
Effective Tax Rate | - | - | - | - | 35.44% | 24.05% |